Intravenous oxpentifylline and the painful crisis of sickle cell disease

K. De Ceulaer, G. R. Serjeant, R. L. Nagel, Henny H. Billett, J. Christakis, D. Loukopoulos, A. J. Bellingham, G. S. Lucas, J. Stuart

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Oxpentifylline, a synthetic xanthine derivative with a rheological action on sickle cells in vitro, has been assessed for the treatment of sickle cell painful crisis in a double-blind, placebo-controlled, multi-centre trial of 62 patients. Oxpentifylline was given as a continuous intravenous infusion for a maximum of 96 hours. No statistically significant difference between the placebo and treatment groups was found for the clinical end-points of resolution of local tenderness, restoration of local movement, overall mobility, sleep disturbance, and complete resolution of symptoms.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalClinical Hemorheology
Volume10
Issue number1
StatePublished - 1990
Externally publishedYes

Fingerprint

Pentoxifylline
Sickle Cell Anemia
Placebos
Xanthine
Intravenous Infusions
Sleep
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Physiology

Cite this

De Ceulaer, K., Serjeant, G. R., Nagel, R. L., Billett, H. H., Christakis, J., Loukopoulos, D., ... Stuart, J. (1990). Intravenous oxpentifylline and the painful crisis of sickle cell disease. Clinical Hemorheology, 10(1), 35-42.

Intravenous oxpentifylline and the painful crisis of sickle cell disease. / De Ceulaer, K.; Serjeant, G. R.; Nagel, R. L.; Billett, Henny H.; Christakis, J.; Loukopoulos, D.; Bellingham, A. J.; Lucas, G. S.; Stuart, J.

In: Clinical Hemorheology, Vol. 10, No. 1, 1990, p. 35-42.

Research output: Contribution to journalArticle

De Ceulaer, K, Serjeant, GR, Nagel, RL, Billett, HH, Christakis, J, Loukopoulos, D, Bellingham, AJ, Lucas, GS & Stuart, J 1990, 'Intravenous oxpentifylline and the painful crisis of sickle cell disease', Clinical Hemorheology, vol. 10, no. 1, pp. 35-42.
De Ceulaer K, Serjeant GR, Nagel RL, Billett HH, Christakis J, Loukopoulos D et al. Intravenous oxpentifylline and the painful crisis of sickle cell disease. Clinical Hemorheology. 1990;10(1):35-42.
De Ceulaer, K. ; Serjeant, G. R. ; Nagel, R. L. ; Billett, Henny H. ; Christakis, J. ; Loukopoulos, D. ; Bellingham, A. J. ; Lucas, G. S. ; Stuart, J. / Intravenous oxpentifylline and the painful crisis of sickle cell disease. In: Clinical Hemorheology. 1990 ; Vol. 10, No. 1. pp. 35-42.
@article{9090ea00b1014d6d8e12c4903d2f3ad2,
title = "Intravenous oxpentifylline and the painful crisis of sickle cell disease",
abstract = "Oxpentifylline, a synthetic xanthine derivative with a rheological action on sickle cells in vitro, has been assessed for the treatment of sickle cell painful crisis in a double-blind, placebo-controlled, multi-centre trial of 62 patients. Oxpentifylline was given as a continuous intravenous infusion for a maximum of 96 hours. No statistically significant difference between the placebo and treatment groups was found for the clinical end-points of resolution of local tenderness, restoration of local movement, overall mobility, sleep disturbance, and complete resolution of symptoms.",
author = "{De Ceulaer}, K. and Serjeant, {G. R.} and Nagel, {R. L.} and Billett, {Henny H.} and J. Christakis and D. Loukopoulos and Bellingham, {A. J.} and Lucas, {G. S.} and J. Stuart",
year = "1990",
language = "English (US)",
volume = "10",
pages = "35--42",
journal = "Clinical Hemorheology and Microcirculation",
issn = "1386-0291",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Intravenous oxpentifylline and the painful crisis of sickle cell disease

AU - De Ceulaer, K.

AU - Serjeant, G. R.

AU - Nagel, R. L.

AU - Billett, Henny H.

AU - Christakis, J.

AU - Loukopoulos, D.

AU - Bellingham, A. J.

AU - Lucas, G. S.

AU - Stuart, J.

PY - 1990

Y1 - 1990

N2 - Oxpentifylline, a synthetic xanthine derivative with a rheological action on sickle cells in vitro, has been assessed for the treatment of sickle cell painful crisis in a double-blind, placebo-controlled, multi-centre trial of 62 patients. Oxpentifylline was given as a continuous intravenous infusion for a maximum of 96 hours. No statistically significant difference between the placebo and treatment groups was found for the clinical end-points of resolution of local tenderness, restoration of local movement, overall mobility, sleep disturbance, and complete resolution of symptoms.

AB - Oxpentifylline, a synthetic xanthine derivative with a rheological action on sickle cells in vitro, has been assessed for the treatment of sickle cell painful crisis in a double-blind, placebo-controlled, multi-centre trial of 62 patients. Oxpentifylline was given as a continuous intravenous infusion for a maximum of 96 hours. No statistically significant difference between the placebo and treatment groups was found for the clinical end-points of resolution of local tenderness, restoration of local movement, overall mobility, sleep disturbance, and complete resolution of symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0025343531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025343531&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0025343531

VL - 10

SP - 35

EP - 42

JO - Clinical Hemorheology and Microcirculation

JF - Clinical Hemorheology and Microcirculation

SN - 1386-0291

IS - 1

ER -